ATE214602T1 - Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten - Google Patents

Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten

Info

Publication number
ATE214602T1
ATE214602T1 AT95942318T AT95942318T ATE214602T1 AT E214602 T1 ATE214602 T1 AT E214602T1 AT 95942318 T AT95942318 T AT 95942318T AT 95942318 T AT95942318 T AT 95942318T AT E214602 T1 ATE214602 T1 AT E214602T1
Authority
AT
Austria
Prior art keywords
antagonist
tumor agent
amplifier including
antibody against
potentiator
Prior art date
Application number
AT95942318T
Other languages
English (en)
Inventor
Osamu Yoshida
Youichi Mizutani
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18336838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE214602(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE214602T1 publication Critical patent/ATE214602T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT95942318T 1994-12-29 1995-12-28 Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten ATE214602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34042594 1994-12-29
PCT/JP1995/002769 WO1996020728A1 (en) 1994-12-29 1995-12-28 Antitumor agent potentiator comprising il-6 antagonist

Publications (1)

Publication Number Publication Date
ATE214602T1 true ATE214602T1 (de) 2002-04-15

Family

ID=18336838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942318T ATE214602T1 (de) 1994-12-29 1995-12-28 Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten

Country Status (11)

Country Link
US (1) US6086874A (de)
EP (1) EP0800829B2 (de)
JP (2) JP4079461B2 (de)
KR (1) KR100252743B1 (de)
CN (1) CN1075387C (de)
AT (1) ATE214602T1 (de)
AU (1) AU704723B2 (de)
CA (1) CA2209124C (de)
DE (1) DE69525971T3 (de)
ES (1) ES2170815T5 (de)
WO (1) WO1996020728A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503939A (en) * 1983-08-19 1985-03-12 Westinghouse Electric Corp. Elevator system
EP2322216A1 (de) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
WO2000044407A2 (en) * 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003037377A1 (fr) * 2001-11-02 2003-05-08 Takeda Chemical Industries Ltd Agents prophylactiques/therapeutiques destines aux maladies des organes a evolution chronique, aux maladies arthritiques chroniques, aux cicatrices hypertrophiques ou cheloides
WO2003039455A2 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
EP2840089A1 (de) * 2002-01-18 2015-02-25 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US20050255103A1 (en) * 2002-04-25 2005-11-17 Chugai Seiyaku Kabushiki Kaisha Remedy for lung cancer
EP1572103A4 (de) * 2002-11-15 2008-02-13 Centocor Inc Verwendungen von il-6-antagonisten gegen die angiogenese
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
WO2005090405A1 (ja) * 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
KR101443050B1 (ko) * 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
JP2009500297A (ja) 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
JP2007091710A (ja) * 2005-08-31 2007-04-12 Ishikawajima Harima Heavy Ind Co Ltd 薬、薬の誘導装置、磁気検出装置及び薬の設計方法
ATE550353T1 (de) * 2005-12-30 2012-04-15 Merck Patent Gmbh Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EP2345974B1 (de) 2006-06-28 2014-08-06 IHI Corporation Magnetisch führbare Verbindung
CN101563365B (zh) * 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
WO2008042611A2 (en) * 2006-09-29 2008-04-10 Centocor, Inc. Method of using il6 antagonists with mitoxantrone for prostate cancer
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CN101246160B (zh) * 2007-09-06 2012-11-21 三峡大学 在体外用ELISA方法建立的IL-6/sIL-6R结合的分子模型
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
ME03057B (de) 2007-12-07 2019-01-20 Zymogenetics Inc Für IL-31 spezifische humanisierte Antikörpermoleküle
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2942392B1 (de) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differenzierung pluripotenter stammzellen
EP2350265B1 (de) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differenzierung menschlicher embryonaler stammzellen in die pankreatisch-endokrine linie
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
AU2009313958B2 (en) * 2008-11-13 2015-09-10 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
CN104800195A (zh) 2008-11-20 2015-07-29 株式会社Ihi 自磁性金属salen络合物
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5317690B2 (ja) 2008-12-27 2013-10-16 株式会社東芝 メモリシステム
WO2011006273A1 (en) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN103952372B (zh) 2009-07-20 2016-10-05 詹森生物科技公司 人胚胎干细胞的分化
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN102712902B (zh) 2009-12-23 2019-01-08 詹森生物科技公司 人胚胎干细胞的分化
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
EP3372672A1 (de) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450544A1 (de) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differenzierung humaner embryonaler stammzellen in endodrine pankreaszellen
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
EP3947737A2 (de) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
US20230293636A1 (en) * 2019-12-31 2023-09-21 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
EP0584251A4 (de) * 1991-05-17 1995-08-02 Seragen Inc Gegen den cytokin-rezeptor gerichtete moleküle zur behandlung des neoplasmatischen zellwachstums.

Also Published As

Publication number Publication date
CA2209124A1 (en) 1996-07-11
CN1075387C (zh) 2001-11-28
DE69525971D1 (de) 2002-04-25
HK1001512A1 (en) 1998-06-26
CA2209124C (en) 2010-03-23
KR100252743B1 (ko) 2000-09-01
JP2008063344A (ja) 2008-03-21
ES2170815T5 (es) 2012-11-14
EP0800829B2 (de) 2012-07-25
EP0800829B1 (de) 2002-03-20
CN1174507A (zh) 1998-02-25
US6086874A (en) 2000-07-11
ES2170815T3 (es) 2002-08-16
JPH08231433A (ja) 1996-09-10
DE69525971T3 (de) 2013-01-10
EP0800829A4 (de) 1999-12-22
AU4356896A (en) 1996-07-24
DE69525971T2 (de) 2002-11-28
JP4079461B2 (ja) 2008-04-23
WO1996020728A1 (en) 1996-07-11
JP4812736B2 (ja) 2011-11-09
EP0800829A1 (de) 1997-10-15
AU704723B2 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
ATE214602T1 (de) Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten
AU6420798A (en) A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
CY1115472T1 (el) Ενωσεις αμινοετεροαρυλιου ως αναστολεις κινασων πρωτεϊνων
NO2018017I1 (no) Interleukin-6 (IL-6) reseptor antistoff (Krav 1 i NO321089). Forlenget SPC
BR9610875A (pt) Modulares rxr seletivos - dimeros e processos para seu uso
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
ATE338565T1 (de) Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)
BR0206364A (pt) Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro
CY1109543T1 (el) Βασικοι μη-πεπτιδικοι ανταγωνιστες βραδυκινινης και 5 φαρμακευτικες συνθεσεις απο αυτους
TR199900090A2 (xx) Benzos�lfon t�revleri
EP0791359A4 (de) Heilmittel gegen von il-6 produktion verurschten krankheiten
DE69631527D1 (de) Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
ATE424560T1 (de) Marker für neuromyelitis optica
DK0929319T3 (da) Dopamin- og serotonintransportörligander og visualiseringsmidler
ATE49118T1 (de) Oral anwendbare antikrebs-zusammensetzungen.
NO980648L (no) Fremgangsmåte for diagnostisk bildeanalyse ved anvendelse av metallkomplekser av nitrogeninneholdende makrocykliske ligander
TR199901636T2 (xx) �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
DE69629411D1 (de) Kompakte Vorrichtung für Retroprojektion
NO980647L (no) Fremgangsmåte for diagnostisk bildeanalyse ved anvendelse av biokonjugater av metallkomplekser av nitrogeninneholdende makrocykliske ligander
TR200001970T2 (tr) MSS bozukluklarının tedavisine mahsus triazin bileşikleri.
TR199900480T2 (xx) Kristalin farmas�tik �r�n.
ATE333702T1 (de) Vorrichtung zur führung von röntgenstrahlen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties